Heparin-induced thrombocytopenia in cancer.

Heparin-induced thrombocytopenia is a common and clinically important drug-induced complication that can cause life- and limbthreatening thrombosis. Epidemiologically, the disease has been studied in many different clinical settings, but little is known about it in cancer patients, a population at increased risk for thrombosis and thus exposure to heparin products. Additionally, thrombocytopenia is a common finding in cancer patients. The convergence of these variables highlights the importance of an increased understanding of the disease in cancer patients.

Duke Scholars

Author Thomas Lee Ortel Medicine, Hematology